medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2013, Number 1

<< Back Next >>

Residente 2013; 8 (1)

Artritis reumatoide y dislipidemias

Mendoza-Vázquez G, Rocha-Muñoz AD, Guerra-Soto AJ, Ramírez-Villafaña M, González-Sánchez AG, Gámez-Nava JI, Nava A

Language: Spanish
References: 33
Page: 12-22
PDF size: 128.07 Kb.


ABSTRACT

The prevalence of rheumatoid arthritis in Mexico is 1.6%, which is the first cause of hospital visits in the Rheumatology Department in secondary level hospitals. Rheumatoid Arthritis is characterized by a chronic inflammatory process and progressive joint destruction that causes disability. Dyslipidemia has been observed in up to 49% of individuals with rheumatoid arthritis. These patients have a mortality rate between 1.3 to 3.9 times that of the general population. In 50% of cases, the cause of death is related to a cardiovascular event. C-reactive protein is an acute phase reactant involved in the pathogenesis of rheumatoid arthritis. In patients with active rheumatoid arthritis there are high concentrations that can alter lipid metabolism. Treatment options for rheumatoid arthritis include disease-modifying drugs and biological agents. These drugs interact with cell surface receptors, causing a modification of proinflammatory cytokines, which in turn modify the lipid profile. The inflammatory state control may positively influence the lipid profile levels.


REFERENCES

  1. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007; 120 (11): 936-939. Review. PubMed PMID: 17976416.

  2. Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63 (5): 508-516. PubMed PMID: 15082480; PubMed Central PMCID: PMC1755008.

  3. Basra G, Jajoria P, Gonzalez E. Rheumatoid arthritis and Swine influenza vaccine: a case report. Case Report Rheumatol. 2012; 2012: 785028. Epub 2012 Jul 3. PubMed PMID: 22953151; PubMed Central PMCID: PMC3420422.

  4. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al. Grupo de Estudio Epidemiológico de Enfermedades Músculo Articulares (GEEMA). Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol. 2011; 86 (Suppl): 3-8. doi: 10.3899/jrheum.100951. Erratum in: J Rheumatol Suppl. 2011; 38 (3): 585. PubMed PMID: 21196592.

  5. Ramos NF, Bernard MG, Lom OH. Manual Clínico de Reumatología. 2a ed. México: Manual Moderno; 2004. p. 79-87.

  6. Goldman L, Bennett JC. Cecil. Tratado de Medicina Interna 21ª ed./ciudad de México: Mcgraw-Hill Interamericana; 2002 p. 1649-57.

  7. Ernesth HS. Choy MD, Gabriel S, Panayi MD. Cytokine pathway sand joint inflammation in rheumatoid arthritis. N Engl J Med. 2001; 344: 907-916.

  8. Schumacher R, Klipper H, Koopman WJ. Compendio de las Enfermedades Reumáticas. Atlanta: Arthritis Foundation, 1993.

  9. Morales J, Cázares JM, Gámez-Nava JI, Triano M, Villa AI, López MA et al. La atención médica en reumatología en un hospital de segundo nivel de atención. Reumatol Clin. 2005; 1: 87-94.

  10. Kilippel JH, Dieppe PA. Principios de las Enfermedades Reumáticas. 12ª ed./Philadelphia: Mosby; 2004 p. 209-32.

  11. O’dell JR. Therapeutic Strategies for Rheumatoid Arthritis. N Eng J Med. 2004; 25: 2591-2602.

  12. Penesova A, Radikova Z, Vlcek M, Kerlik J, Lukac J, Rovensky J et al. Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors. Physiol Res. 2012 Nov 22. [Epub ahead of print] PubMed PMID:23173679.

  13. Giles JT, Bartlett SJ, Andersen R, Thompson R, Fontaine KR, Bathon JM. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum. 2008; 58 (9): 2632-2641. PubMed PMID: 18759279; PubMed Central PMCID: PMC2671067.

  14. Shegarfi H, Naddafi F, Mirshafiey A. Natural killer cells and their role in rheumatoid arthritis: friend or foe? Sci World J. 2012; 2012: 491974. Epub 2012 Apr 1. Review. PubMed PMID: 22547986; PubMed Central PMCID: PMC3322405.

  15. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/NEJMra1004965. Review. PubMed PMID: 22150039.

  16. Vennapusa B, De La Cruz L, Shah H, Michalski V, Zhang QY. Erythrocyte sedimentation rate (ESR) measured by the Streck ESR-Auto Plus is higher than with the SediplastWestergren method: a validation study. Am J Clin Pathol. 2011; 135 (3): 386-390. PubMed PMID: 21350092.

  17. Águila CA, Gómez FJ, Garber IL, Vázquez C, Pérez O, Posadas C. Diagnóstico y tratamiento de las dislipidemias. Rev Endocrinol Nutr. 2004; 12: 7-41.

  18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17; 106 (25): 3143-421. PubMed PMID: 12485966.

  19. Norma Oficial Mexicana NOM-037-SSA2-2002 para la Prevención, Tratamiento y Control de las Dislipidemias.

  20. Dursunoglu D, Evrengül H, Polat B, Tanriverdi H, Cobankara V, Kaftan A et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation. Rheumatol Int. 2005; 25: 241-245.

  21. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: A population-based study. Arthritis Rheum. 2005; 52: 722-732.

  22. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59: 1690-1677.

  23. Nurmohamed MT, Dijkmans BA. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis. 2009; 68: 453-455.

  24. Pérez MJ, Salvatierra J, Cáliz R, Guzmán MA. Influencia del bloqueo del factor de necrosis tumoral alfa (infliximab) en el metabolismo lipídico de pacientes con artritis reumatoide. Med Clin (Barc). 2006; 126: 757-759.

  25. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;16; 108: 2957-2963.

  26. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med. 2006; 144: 249-256.

  27. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002; 46: 862-873.

  28. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis. 1997; 56: 374-377.

  29. Arce C. Glucocorticoides en Artritis Reumatoide, ¿Hacia qué lado se inclina la balanza? Rev Mex Reumatol. 2001; 16: 373-376.

  30. Ibáñez A, Berrocal A, Calvo A. Terapia con glucocorticoides en artritis reumatoide. Diagnóstico. 2002; 41-4.

  31. vanHalm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: A case control study. Arthritis Res Ther. 2006; 8: R151.

  32. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet. 2002; 359: 1173-1177.

  33. Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008; 10: R30.




2020     |     www.medigraphic.com